Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medical Research Council | OTHER_GOV |
| Alzheimer's Society | OTHER |
Primary Aim
To determine whether;
Secondary Aims
To determine whether;
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Donepezil | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Cohen Mansfield Agitation Inventory |
| Measure | Description | Time Frame |
|---|---|---|
| Neuropsychiatric Inventory | ||
| Standardized Mini-Mental State Examination | ||
| Severe Impairment Battery |
Not provided
Inclusion Criteria: a diagnosis of dementia consistent with Diagnostic and Statistical Manual of Mental Health Disorders, revised 3rd edition (DSM-III-R) (APA, 1987) National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probably or possible AD (MKhann et al, 1984) (Appendix 6) clinically significant agitation (defined as causing distress to patient and at least moderate management problems for carers on at least two days per week for a two week period, together with a Cohen Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield, 1986) (Appendix 11 A) score >39 age >39 years resident in care facility or community living with a carer not receiving treatment with neuroleptics or cholinesterase inhibitors currently or in the past four weeks and responsible clinician not considering treatment with cholinesterase inhibitor for the next 16 weeks taking into account the clinical evidence base and NICE guideline (NICE, 2001) patient with capacity willing to consent to study or will to participate in study if lacking capacity carer with capacity willing to consent to study and in agreement for patient lacking capacity to participate if patient willing to participate
-
Exclusion Criteria:known sensitivity to Donepezil severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations current evidence of delirium patient meets criteria for Probably Dementia with Lewy Bodies (McKeith et al, 1996) low probability of treatment compliance
-
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert Howard | Institute of Psychiatry, London | Principal Investigator |
| Peter Bentham | Queen Elizabeth Psychiatric Hospital, Birmingham | Principal Investigator |
| Richard Brown | Institute of Psychiatry, London | Principal Investigator |
| Roger Bullock | Kingshill Research Centre, Victoria Hospital, Swindon | Principal Investigator |
| Alistair Burns | Wythenshawe Hospital, Manchester | Principal Investigator |
| Clive Holmes | Moorgreen Hospital, Southampton | Principal Investigator |
| Robin Jacoby | Warneford Hospital, Oxford | Principal Investigator |
| James Lindesay | Leicester General Hospital, Leicester | Principal Investigator |
| John O'Brien | Newcastle General Hospital, Newcastle | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Queen Elizabeth Psychiatric Hospital | Birmingham | B15 2QZ | United Kingdom | |||
| Department of Psychiatry for the Elderly, Leicester General Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 17914039 | Derived | Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007 Oct 4;357(14):1382-92. doi: 10.1056/NEJMoa066583. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D003704 | Dementia |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077265 | Donepezil |
| ID | Term |
|---|---|
| D007189 | Indans |
| D007192 | Indenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Clinical Global Impression of Severity/Change |
| Leicester |
| LE5 4PW |
| United Kingdom |
| Institute of Psychiatry, King's College, London | London | SE5 8AF | United Kingdom |
| Old Age Psychiatry, Wythenshawe Hospital, Manchester | Manchester | M23 9LT | United Kingdom |
| Institute for Ageing and Health, Newcastle General Hospital, Newcastle | Newcastle upon Tyne | NE4 6BE | United Kingdom |
| Department of Psychiatry, Warneford Hospital, Oxford | Oxford | OX3 7JX | United Kingdom |
| MARC, Moorgreen Hospital, Southamptom | Southampton | S030 3JB | United Kingdom |
| Department of Old Age Psychiatry, Victoria Hospital, Swindon | Swindon | SN1 4HZ | United Kingdom |
| D019636 |
| Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D006844 |
| Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011083 | Polycyclic Compounds |